These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
46. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930 [TBL] [Abstract][Full Text] [Related]
47. Evaluation of a Edem PE; Jørgensen JT; Nørregaard K; Rossin R; Yazdani A; Valliant JF; Robillard M; Herth MM; Kjaer A Molecules; 2020 Jan; 25(3):. PubMed ID: 31979070 [TBL] [Abstract][Full Text] [Related]
48. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy. Luyten K; Van Loy T; Cawthorne C; Deroose CM; Schols D; Bormans G; Cleeren F Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683912 [TBL] [Abstract][Full Text] [Related]
49. Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers. Ogawa K; Ishizaki A; Takai K; Kitamura Y; Kiwada T; Shiba K; Odani A PLoS One; 2013; 8(12):e84335. PubMed ID: 24391942 [TBL] [Abstract][Full Text] [Related]
50. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107 [TBL] [Abstract][Full Text] [Related]
51. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915 [TBL] [Abstract][Full Text] [Related]
52. Clinical evaluation of [ Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872 [TBL] [Abstract][Full Text] [Related]
54. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis. Prinsen K; Cona MM; Cleynhens BJ; Li J; Vanbilloen H; Dyubankova N; Lescrinier E; Ni Y; Bormans GM; Verbruggen AM Nucl Med Biol; 2013 Aug; 40(6):816-22. PubMed ID: 23915800 [TBL] [Abstract][Full Text] [Related]
55. Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy. Souche C; Fouillet J; Rubira L; Donzé C; Deshayes E; Fersing C Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203632 [TBL] [Abstract][Full Text] [Related]
56. Syntheses and evaluation of Chakraborty S; Goswami D; Chakravarty R; Mohammed SK; Sarma HD; Dash A Chem Biol Drug Des; 2018 Sep; 92(3):1618-1626. PubMed ID: 29729071 [TBL] [Abstract][Full Text] [Related]
57. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging. Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572 [TBL] [Abstract][Full Text] [Related]